NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial is designed to enroll up to 20 patients with varying disease severity and is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity. This matters because Ebola remains a high-fatality viral disease with limited treatment options, and an oral, broad-spectrum antiviral could be easier to deploy in outbreak settings than injectable therapies.
Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. If successful, this approach could lead to a platform capable of addressing multiple viral threats, including those with pandemic potential. The company's pipeline includes NV-387 for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Another advanced candidate is NV-HHV-1 for the treatment of Shingles. For investors, the progress in the Ebola trial represents a critical milestone in validating the company's nanoviricide technology and could pave the way for broader applications.
The trial's outcome will be closely watched as a signal of whether NV-387 can move into later-stage testing. NanoViricides cannot project an exact date for filing an IND for any of its drugs because of dependence on external collaborators and consultants. The company is currently focused on advancing NV-387 into Phase II human clinical trials. For more details, the full press release is available at https://nnw.fm/9fDB5. The latest news and updates relating to NNVC are available in the company's newsroom at https://nnw.fm/NNVC. NanoViricides' corporate website is www.nanoviricides.com.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. This distribution network helps ensure that developments like NanoViricides' Ebola trial reach a wide audience of investors and industry observers. As with any drug development effort, there can be no assurance that any pharmaceutical candidate will show sufficient effectiveness and safety for human clinical development.
